Gene · 2197
FAU: FAU ubiquitin like and ribosomal protein S30 fusion
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. FAU: FAU ubiquitin like and ribosomal protein S30 fusion. Genes, record 2197. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/2197
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P62861 | Ubiquitin-like FUBI-ribosomal protein eS30 fusion protein | 133 | 195 | Ensembl, GeneID, HGNC |
Source UniProt
Patents33
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 46367 | P62861 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 46369 | P62861 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 46370 | P62861 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 15458 | P62861 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 7575 | P62861 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 15458 | P62861 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 7575 | P62861 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 32175 | P62861 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 32177 | P62861 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 32179 | P62861 | Espacenet |
1 to 10 of 33
See all 33 patentsDrugs9
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ATALUREN | CHEMBL256997 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| CITATUZUMAB BOGATOX | CHEMBL1743000 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| CYCLOHEXIMIDE | CHEMBL123292 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| DORLIMOMAB ARITOX | CHEMBL2109124 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ELX-02 | CHEMBL4297744 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| MT-3724 | CHEMBL4297789 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TAPLITUMOMAB PAPTOX | CHEMBL2107890 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TELIMOMAB ARITOX | CHEMBL2108790 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ZOLIMOMAB ARITOX | CHEMBL2108785 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
Trials38
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07523581 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT05448755 | ELX-02 | PHASE2 | 2026-02-24 | ClinicalTrials.gov |
| NCT04336826 | ATALUREN | PHASE2 | 2024-04-01 | ClinicalTrials.gov |
| NCT04135495 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04126473 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04117880 | ATALUREN | PHASE2 | ClinicalTrials.gov | |
| NCT04069260 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04014530 | ATALUREN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT03796637 | ATALUREN | PHASE2 | 2022-04-05 | ClinicalTrials.gov |
| NCT03645395 | MT-3724 | PHASE2 | 2022-08-16 | ClinicalTrials.gov |
1 to 10 of 38
See all 38 trialsNIH grants446
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | FAU papers | Newest fiscal year |
|---|---|---|---|
| P30CA016086 | Cancer Center Support Grant | 3 | 2025 |
| P30CA022453 | CANCER CENTER SUPPORT GRANT | 3 | 2025 |
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 2 | 2025 |
| P30CA014195 | Cancer Center Support Grant (CCSG) | 2 | 2025 |
| R01GM144367 | Structural and Functional Analysis of Proteasome Core Particle Biogenesis | 2 | 2025 |
| P01HL131478 | Stress-induced immune reprogramming in cardiovascular disease | 1 | 2025 |
| P20GM103418 | Kansas IDeA Network of Biomedical Research Excellence 5 | 1 | 2025 |
| P20GM103476 | Mississippi INBRE | 1 | 2025 |
| P20GM113132 | The Institute for Biomolecular Targeting | 1 | 2025 |
| P20GM121176 | Autophagy, Inflammation and Metabolism (AIM) in Disease Center - Phase 2. | 1 | 2025 |
1 to 10 of 446Source NIH's project files
See all 446 nih grantsPapers734
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| [Mining of ancestral lipases and enzymatic synthesis of amides]. | Sheng Wu Gong Cheng Xue Bao | 2026 | 42343804 | PubTator, text mining | PubMed |
| Integrative Transcriptomic, Network, and Genomic Analysis of Peripheral Blood Mononuclear Cells Identifies Candidate Genes Associated with Dupilumab Clinical Response in Atopic Dermatitis Patients. | Int J Mol Sci | 2026 | 42278672 | PubTator, text mining | PubMed |
| Lipocentric Non-Pore-Forming Membrane Depolarization Underlies the Antibacterial Activity of Ribosomal Protein S30. | J Phys Chem Lett | 2026 | 41943536 | PubTator, text mining | PubMed |
| Biosynthesis of zinc oxide and silver/zinc oxide nanocompositesusing Kalanchoe pinnata leaf extracts for antibacterial and anticancer applications. | Discov Nano | 2026 | 41931199 | PubTator, text mining | PubMed |
| Maternal opioid use disorder and hepatitis C infection in pregnancy reshape the peripheral immune landscape at term. | EBioMedicine | 2026 | 41849830 | PubTator, text mining | PubMed |
| Synthetic Strategies for Activity-Based Probes to Decode Ubiquitin-Like Modifiers. | Chemistry | 2026 | 41728666 | PubTator, text mining | PubMed |
| From Covalent Traps to Fluorescent Beacons: The Expanding Arsenal of Chemical Probes for Studying Ubiquitin and Ubiquitin-Like Proteins. | Angew Chem Int Ed Engl | 2026 | 41673774 | PubTator, text mining | PubMed |
| Single-cell spatial transcriptomics uncovers niches that govern response to PD-1/PD-L1 blockade in cutaneous squamous cell carcinoma. | J Immunother Cancer | 2026 | 41617396 | PubTator, text mining | PubMed |
| Combining Mesoporosity and Shape Selectivity in FAU-MFI Interzeolite Intermediates for Renewable Xylenes Production. | ACS Sustain Chem Eng | 2026 | 41541633 | PubTator, text mining | PubMed |
| Venetoclax induces mitochondrial apoptosis and autophagy to overcome arsenic trioxide resistance in acute promyelocytic leukemia. | J Transl Med | 2026 | 41527127 | PubTator, text mining | PubMed |
1 to 10 of 734
See all 734 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/2197
GET https://conductscience.org/api/genes/v1/2197/patents?page=2